These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38117670)

  • 1. Untargeted Detection of HIF Stabilizers in Doping Samples: Activity-Based Screening with a Stable In Vitro Bioassay.
    Janssens LK; De Wilde L; Van Eenoo P; Stove CP
    Anal Chem; 2024 Jan; 96(1):238-247. PubMed ID: 38117670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.
    Dib J; Mongongu C; Buisson C; Molina A; Schänzer W; Thuss U; Thevis M
    Drug Test Anal; 2017 Jan; 9(1):61-67. PubMed ID: 27346747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case.
    Buisson C; Marchand A; Bailloux I; Lahaussois A; Martin L; Molina A
    J Pharm Biomed Anal; 2016 Mar; 121():181-187. PubMed ID: 26808067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.
    Eichner D; Van Wagoner RM; Brenner M; Chou J; Leigh S; Wright LR; Flippin LA; Martinelli M; Krug O; Schänzer W; Thevis M
    Drug Test Anal; 2017 Nov; 9(11-12):1768-1778. PubMed ID: 28378453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated sample preparation for the detection and confirmation of hypoxia-inducible factor stabilizers in urine.
    De Wilde L; Roels K; Deventer K; Van Eenoo P
    Biomed Chromatogr; 2021 Feb; 35(2):e4970. PubMed ID: 32840903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research.
    Beuck S; Bornatsch W; Lagojda A; Schänzer W; Thevis M
    Drug Test Anal; 2011; 3(11-12):756-70. PubMed ID: 22213684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis.
    Beuck S; Schänzer W; Thevis M
    Drug Test Anal; 2012 Nov; 4(11):830-45. PubMed ID: 22362605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic studies of hypoxia-inducible factor stabilisers IOX2, IOX3 and IOX4 (in vitro) for doping control.
    Philip M; Mathew B; Karatt TK; Perwad Z; Subhahar MB; Karakka Kal AK
    Drug Test Anal; 2021 Apr; 13(4):794-816. PubMed ID: 33458935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Hypoxia-inducible factor (HIF) stabilizer roxadustat and its possible metabolites in thoroughbred horses for doping control.
    Mathew B; Philip M; Perwad Z; Karatt TK; Caveney MR; Subhahar MB; Karakka Kal AK
    Drug Test Anal; 2021 Jun; 13(6):1203-1215. PubMed ID: 33569900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry.
    Görgens C; Guddat S; Thomas A; Wachsmuth P; Orlovius AK; Sigmund G; Thevis M; Schänzer W
    J Pharm Biomed Anal; 2016 Nov; 131():482-496. PubMed ID: 27693991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
    Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
    Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UPLC-MS-Based Procedures to Detect Prolyl-Hydroxylase Inhibitors of HIF in Urine.
    Mazzarino M; Perretti I; Stacchini C; Comunità F; de la Torre X; Botrè F
    J Anal Toxicol; 2021 Feb; 45(2):184-194. PubMed ID: 32435795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Hypoxia-Regulated MicroRNAs in Blood as Potential Biomarkers of HIF Stabilizer Molidustat.
    Marchand A; Roulland I; Semence F; Schröder K; Domergue V; Audran M
    Microrna; 2019; 8(3):189-197. PubMed ID: 30657053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence flow cytometer to determine urine particle reference intervals in doping control samples.
    Robinson N; Sottas PE; Saugy M
    Forensic Sci Int; 2011 Dec; 213(1-3):95-100. PubMed ID: 21889276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of the HIF activator IOX-2 in routine doping controls - Pilot study data.
    Görgens C; Guddat S; Bosse C; Knoop A; Geyer H; Thevis M
    Drug Test Anal; 2020 Nov; 12(11-12):1614-1619. PubMed ID: 32809277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico and in vitro human metabolism of IOX2, a performance-enhancing doping agent.
    Taoussi O; Gameli PS; Berardinelli D; Busardò FP; Tini A; Carlier J
    J Pharm Biomed Anal; 2024 Jan; 238():115759. PubMed ID: 37866082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis.
    Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
    J Pharm Biomed Anal; 2023 Oct; 235():115600. PubMed ID: 37516063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry.
    Knoop A; Krug O; Vincenti M; Schänzer W; Thevis M
    Eur J Mass Spectrom (Chichester); 2015; 21(1):27-36. PubMed ID: 25906032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the metabolites of the HIF stabilizer FG-4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry.
    Hansson A; Thevis M; Cox H; Miller G; Eichner D; Bondesson U; Hedeland M
    J Pharm Biomed Anal; 2017 Feb; 134():228-236. PubMed ID: 27918992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.